GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » EV-to-EBITDA

InflaRx NV (InflaRx NV) EV-to-EBITDA : 0.55 (As of May. 09, 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InflaRx NV's enterprise value is $-25.18 Mil. InflaRx NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.43 Mil. Therefore, InflaRx NV's EV-to-EBITDA for today is 0.55.

The historical rank and industry rank for InflaRx NV's EV-to-EBITDA or its related term are showing as below:

IFRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.89   Med: 0.19   Max: 1.25
Current: 0.55

During the past 9 years, the highest EV-to-EBITDA of InflaRx NV was 1.25. The lowest was -0.89. And the median was 0.19.

IFRX's EV-to-EBITDA is ranked better than
79.52% of 454 companies
in the Biotechnology industry
Industry Median: 10.055 vs IFRX: 0.55

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), InflaRx NV's stock price is $1.20. InflaRx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.864. Therefore, InflaRx NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


InflaRx NV EV-to-EBITDA Historical Data

The historical data trend for InflaRx NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV EV-to-EBITDA Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 0.41 -1.09 -2.32 -1.75 0.03

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.75 -0.56 -4.20 -1.48 0.03

Competitive Comparison of InflaRx NV's EV-to-EBITDA

For the Biotechnology subindustry, InflaRx NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InflaRx NV's EV-to-EBITDA falls into.



InflaRx NV EV-to-EBITDA Calculation

InflaRx NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-25.179/-45.427
=0.55

InflaRx NV's current Enterprise Value is $-25.18 Mil.
InflaRx NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV  (NAS:IFRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InflaRx NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.20/-0.864
=At Loss

InflaRx NV's share price for today is $1.20.
InflaRx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.864.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


InflaRx NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InflaRx NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.